Insmed Inc (INSM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Insmed Inc (INSM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10027
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Insmed Inc (Insmed) is a biopharmaceutical company that focuses on rare diseases. Its lead product candidate, Arikayce (liposomal amikacin for inhalation), is indicated for the treatment of nontuberculous mycobacteria (NTM) lung disease in adult patients. Its other clinical pipeline are being developed for pulmonary arterial hypertension (PAH), severe refractory asthma, for chronic inflammatory lung diseases such as non-cystic fibrosis (non-CF) bronchiectasis and for nontuberculous mycobacterial lung infection and chronic Pseudomonas aeruginosa in non-CF bronchiectasis. The company has offices in the US, the UK, Ireland, the Netherlands, Germany and France. Insmed is headquartered in Bridgewater, New Jersey, the US.

Insmed Inc (INSM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Insmed Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9
Insmed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Insmed Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Insmed Enters into Agreement with National Institutes of Allergy and Infectious Diseases 11
Licensing Agreements 12
Insmed Enters into Licensing Agreement with AstraZeneca 12
Premacure Amends Licensing Agreement with Insmed 14
Equity Offering 15
Insmed Raises USD402 Million in Public Offering of Shares 15
Insmed Raises USD237.4 Million in Public Offering of Common Stock 17
Insmed Raises USD115 Million in Public Offering of Shares 19
Insmed Completes Public Offering Of Shares For US$71.8 Million 21
Insmed Completes Public Offering Of Common Stock For US$26 Million 23
Debt Offering 24
Insmed Raises USD450 Million in Public Offering of 1.75% Notes Due 2025 24
Insmed Inc – Key Competitors 26
Insmed Inc – Key Employees 27
Insmed Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Oct 30, 2018: Insmed reports third quarter 2018 financial results and provides business update 29
Aug 02, 2018: Insmed reports second quarter 2018 financial Results and provides business update 31
May 02, 2018: Insmed Reports First Quarter 2018 Financial Results and Provides Business Update 33
Feb 23, 2018: Insmed Reports Fourth Quarter 2017 Financial Results 34
Nov 02, 2017: Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update 36
Aug 03, 2017: Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update 37
May 03, 2017: Insmed Reports First Quarter 2017 Financial Results 38
May 03, 2017: Insmed Q1 net loss increases 39
Feb 23, 2017: Insmed Reports Fourth Quarter 2016 Financial Results and Provides Business Update 40
Corporate Communications 41
May 15, 2017: Insmed Announces Key Additions to its Executive Management Team 41
Clinical Trials 42
May 03, 2017: Insmed Provides Update On Phase 2 Study Of INS1007 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Insmed Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Insmed Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Insmed Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9
Insmed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Insmed Enters into Agreement with National Institutes of Allergy and Infectious Diseases 11
Insmed Enters into Licensing Agreement with AstraZeneca 12
Premacure Amends Licensing Agreement with Insmed 14
Insmed Raises USD402 Million in Public Offering of Shares 15
Insmed Raises USD237.4 Million in Public Offering of Common Stock 17
Insmed Raises USD115 Million in Public Offering of Shares 19
Insmed Completes Public Offering Of Shares For US$71.8 Million 21
Insmed Completes Public Offering Of Common Stock For US$26 Million 23
Insmed Raises USD450 Million in Public Offering of 1.75% Notes Due 2025 24
Insmed Inc, Key Competitors 26
Insmed Inc, Key Employees 27
Insmed Inc, Subsidiaries 28

List of Figures
Insmed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Insmed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Insmed Inc (INSM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fortis Inc (FTS):電力:M&Aディール及び事業提携情報
    Summary Fortis Inc (Fortis) is an oil and gas company that provides development of assets and market capitalization programs. The company offers measurement and monitoring of environmental impacts. It also provides capital program and growth plans to meet the energy needs. Fortis support and partici …
  • Roper Technologies Inc (ROP):医療機器:M&Aディール及び事業提携情報
    Summary Roper Technologies Inc (Roper), formerly Roper Industries Inc, is a diversified technology company. It designs and develops software, and engineered products and solutions. It offers both software-as-a-service and licensed to customers. The company serves healthcare, water, food, transportat …
  • Forterra, Inc. (FRTA):企業の財務・戦略的SWOT分析
    Forterra, Inc. (FRTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Exxon Mobil Corporation:企業の戦略・SWOT・財務情報
    Exxon Mobil Corporation - Strategy, SWOT and Corporate Finance Report Summary Exxon Mobil Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Admedes GmbH:企業の戦略的SWOT分析
    Admedes GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Central Iowa Power Cooperative:企業の戦略的SWOT分析
    Central Iowa Power Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Kansas City Power & Light Co:企業の戦略的SWOT分析
    Kansas City Power & Light Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • KnowBe4 Inc:企業の戦略的SWOT分析
    KnowBe4 Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Mytrus Inc-製薬・医療分野:企業M&A・提携分析
    Summary Mytrus Inc (Mytrus) is an e-clinical technology company that specializes in patient-centered electronic informed consent and data collection tools. The company’s technology includes Enroll, an electronic informed consent and patient enrollment system for clinical trials. Mytrus develops new …
  • SNC-Lavalin Group Inc.:企業のM&A・事業提携・投資動向
    SNC-Lavalin Group Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SNC-Lavalin Group Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Kuwait Food Company (Americana) KSCP:企業の戦略的SWOT分析
    Kuwait Food Company (Americana) KSCP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Avisa Pharma Inc:医療機器:M&Aディール及び事業提携情報
    Summary Avisa Pharma Inc (Avisa Pharma) is a medical device company that develops breath tests system for the diagnosis of pulmonary infections. The company provides product such as avisa breath test kit, which is designed to detect respiratory bacterial infections in the lung and other metabolic di …
  • Cellectar Biosciences Inc (CLRB):製薬・医療:M&Aディール及び事業提携情報
    Summary Cellectar Biosciences Inc (Cellectar) develops phospholipid drug conjugates (PDCs) for the treatment and diagnosis of cancer. Its lead product, CLR 131, is a small-molecule radiotherapeutic PDC, being developed for the treatment of relapse or refractory multiple myeloma. Cellectar’s other pr …
  • NuGEN Technologies Inc-製薬・医療分野:企業M&A・提携分析
    Summary NuGEN Technologies Inc (NuGEN) is a provider of biological science reagents. The company offers DNA and RNA sample preparation products for use in research and diagnostic applications. Its products include Next-Gen Sequencing applications, which include RNA-Seq, targeted resequencing of DNA …
  • Loral Space & Communications Inc. (LORL):企業の財務・戦略的SWOT分析
    Loral Space & Communications Inc. (LORL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Petoro AS:企業の戦略的SWOT分析
    Petoro AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Edisun Power Europe AG (ESUN):電力:M&Aディール及び事業提携情報
    Summary Edisun Power Europe AG (Edisun Power) is a solar power producer. The company finances, develops and operates solar power plants in various European countries. It offers technical studies, legal and financial studies, custom design, installation, work monitoring, and operation and maintenance …
  • Aminex PLC (AEX):企業の財務・戦略的SWOT分析
    Summary Aminex PLC (Aminex) is an oil and gas company that explores, develops and produces oil and gas reserves in Africa. The company provides assets such as Valeni field and Viktorovka field in Moldova; West Esh el Mellaha-2 in Egypt; and Kiliwani North development, Nyuni exploration, and Ruvuma e …
  • Mitsubishi Corporation:戦略・SWOT・企業財務分析
    Mitsubishi Corporation - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Pulai Group:企業の戦略・SWOT・財務分析
    Pulai Group - Strategy, SWOT and Corporate Finance Report Summary Pulai Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆